Syndromic testing – the future of molecular diagnostics
Syndromic testing with the QIAstat-Dx system allows you to rapidly and simultaneously survey a large number of pathogens in a single sample. This means you can get comprehensive diagnostic answers in around an hour. And patients can get the right treatment faster.
To learn more about the benefits of QIAstat-Dx syndromic testing and hear about the latest insights on molecular diagnostics for infectious disease, watch our most recent webinars.
Watch the webinars
-
Learn how rapid diagnostic tools can support antimicrobial stewardship programs
Title: Impact of antimicrobial stewardship intervention in conjunction with rapid multiplex respiratory diagnostics
Speaker: Eric Wenzler, PharmD, BCPS, BCIDP, AAHIVP, Department of Pharmacy Practice, University of Illinois, Chicago College of Pharmacy, USA
Quickly distinguishing between viral and bacterial causes of respiratory illness can lead to optimized antibacterial and antiviral use and assist with decisions on hospital admission and infection control. In this webinar, Dr. Wenzler explains how multiplex respiratory panels can enable quick and definitive pathogen identification to support antimicrobial stewardship efforts and optimize clinical and economic outcomes.
-
Learn about the role of multiplex testing in the COVID-19 pandemic
Title: Tackling COVID-19 through syndromic testing – QIAstat-Dx Respiratory SARS-CoV-2
Speaker: Davide Manissero, MD, MRCPCH, MSc, DTM&H, VP Head of Medical Affairs & Chief Medical Officer, Infection & Immune Diagnostics, QIAGENDuring this webinar, QIAGEN Chief Medical Officer Dr. Davide Manissero will discuss the role of multiplex respiratory PCR testing in the ongoing COVID-19 pandemic and how QIAGEN ramped up development efforts to be the first syndromic solution on the market. The importance of time to diagnosis and potential for co-infections as we approach the 2020-2021 influenza season will be discussed.
-
Learn about the benefits of syndromic testing for acute respiratory illness
Title: A new multiplex syndromic system for respiratory diagnosis and improved patient care
Speaker: Dr. Steve Young, Director of Research and Clinical Trials, TriCore Reference LaboratoriesThis webinar discusses how a new multiplexed testing system can help physicians rapidly diagnose acute respiratory infections. Acute respiratory tract infections are caused by a wide range of viral and bacterial pathogens and may share similar clinical presentations that make it difficult for physicians to diagnose based on symptoms alone. Syndromic testing with multiplex molecular panels offers clinical labs a way to quickly distinguish between a broad array of respiratory pathogens. In this webinar, Dr. Steve Young of Tricore Reference Laboratories presents a new technology for multiplexed respiratory testing in acutely ill patients. He shares data demonstrating the capabilities of syndromic respiratory testing as well as his impressions on the ease of doing comprehensive syndromic testing using the QIAstat-Dx Analyzer.
-
Learn how rapid diagnostic tools can support antimicrobial stewardship programs
-
Learn about the role of multiplex testing in the COVID-19 pandemic
-
Learn about the benefits of syndromic testing for acute respiratory illness
QIAstat-Dx resources and further reading
The QIAstat-Dx Analyzer is intended for in vitro diagnostic use.
The QIAstat-Dx Respiratory SARS-CoV-2 Panel is intended for in vitro diagnostic use.
- This product has not been FDA cleared or approved, but has been authorized for emergency use by FDA under an EUA for use by authorized laboratories;
- This product has been authorized only for the detection and differentiation of nucleic acid of SARS-CoV-2 from multiple respiratory viral and bacterial organisms; and
- This emergency use of this product is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostics for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Federal Food, Drug, and Cosmetics Act, 21 U.S.C. § 360bbb-3(b)(1), unless the declarations is terminated or authorization is revoked sooner.
- Products and product claims may differ from country to country based on regulations and approvals. Contact your country representative for further details.